Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) EBT: 2009-2025

Historic EBT for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $2.0 million.

  • Aytu Biopharma's EBT rose 31.17% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.3 million, marking a year-over-year decrease of 843.71%. This contributed to the annual value of -$13.7 million for FY2025, which is 32.44% down from last year.
  • Per Aytu Biopharma's latest filing, its EBT stood at $2.0 million for Q3 2025, which was up 110.11% from -$19.4 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's EBT ranged from a high of $3.8 million in Q1 2025 and a low of -$53.3 million during Q1 2022.
  • Over the past 3 years, Aytu Biopharma's median EBT value was -$1.8 million (recorded in 2024), while the average stood at -$2.9 million.
  • In the last 5 years, Aytu Biopharma's EBT tumbled by 966.05% in 2023 and then skyrocketed by 316.07% in 2025.
  • Aytu Biopharma's EBT (Quarterly) stood at -$11.6 million in 2021, then skyrocketed by 42.06% to -$6.7 million in 2022, then surged by 120.90% to $1.4 million in 2023, then tumbled by 72.69% to $382,000 in 2024, then soared by 31.17% to $2.0 million in 2025.
  • Its EBT stands at $2.0 million for Q3 2025, versus -$19.4 million for Q2 2025 and $3.8 million for Q1 2025.